Biohaven shares jumped 25% Thursday after the FDA accepted the company’s resubmitted new drug application for troriluzole, marketed as Vyglxia, in spinocerebellar ataxia. The move put $BHVN on pace for its biggest single-day gain in four years in premarket trading, according to reports from Investing.com and Yahoo Finance.

For traders, the headline catalyst is clear: a 25% move tied to a meaningful regulatory milestone. But the distinction between FDA acceptance and final approval is equally important. The agency has accepted the resubmitted filing for review; that does not mean Vyglxia has been approved for patients with spinocerebellar ataxia.

Why the filing acceptance matters

The FDA’s acceptance follows a prior resubmission by Biohaven addressing deficiencies identified in the earlier filing. That sequence gives the announcement more weight than a routine corporate update: the company has now cleared another procedural hurdle in its effort to advance troriluzole through the regulatory process.

Acceptance indicates that the resubmitted application is sufficiently complete for the FDA to review. It does not resolve the ultimate question of whether the agency will approve the drug. For $BHVN traders, that creates a catalyst with two separate layers: an immediate market reaction to the filing milestone and a longer regulatory path that remains unresolved.

The trader’s read on a 25% move

• Magnitude: Shares jumped 25% Thursday, a large one-session reaction to the FDA announcement.
• Historical context: The stock was on pace for its biggest single-day gain in four years in premarket trading.
• Event type: The catalyst was acceptance of a resubmitted new drug application, not final approval.
• Regulatory backdrop: The resubmission addressed prior FDA deficiencies, but the eventual decision remains pending.

That framework matters because a sharp biotech move can reflect a change in expectations without settling the underlying regulatory outcome. The 25% jump suggests traders viewed the filing acceptance as a material reduction in uncertainty around the application’s progress. It does not, by itself, establish that the FDA will approve Vyglxia.

What remains ahead for Vyglxia

The next major issue is the FDA’s review of the resubmitted application for troriluzole in SCA. The available information confirms acceptance and the company’s response to earlier deficiencies, but it does not provide a final regulatory decision. Any further assessment of $BHVN therefore hinges on developments in that review rather than on the acceptance announcement alone.

For now, Biohaven has delivered a clearly defined biotech catalyst: a resubmitted Vyglxia filing accepted by the FDA and a 25% stock move. The bullish interpretation centers on regulatory progress. The counterpoint is that acceptance is a review milestone, not a guarantee of approval.